Literature DB >> 3493519

Acute otitis media caused by Branhamella catarrhalis: biology and therapy.

G F Van Hare, P A Shurin, C D Marchant, N A Cartelli, C E Johnson, D Fulton, S Carlin, C H Kim.   

Abstract

Since 1980, we have observed an epidemic of otitis media caused by Branhamella catarrhalis. This event was characterized by studying the nasopharyngeal colonization of infants and children with B. catarrhalis and the clinical presentation and therapeutic outcome of acute otitis media caused by this organism. Pharyngeal colonization with B. catarrhalis was commoner in winter than summer. B. catarrhalis was present in middle-ear fluid (MEF) of 17% of children with otitis media, and was commoner in fall and winter (20%) than in spring and summer (11%, P less than .05). Seventy-five percent of isolates produced beta-lactamase (Ravasio type). In five of 20 patients, treatment with beta-lactamase-susceptible agents failed to sterilize B. catarrhalis-infected MEF. All of these five patients were infected with beta-lactamase-producing strains. The increasing prominence of antibiotic-resistant B. catarrhalis in acute otitis media may lead to a reevaluation of initial antibiotic therapy for acute otitis media, particularly in winter or in areas where colonization with such strains is prevalent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493519     DOI: 10.1093/clinids/9.1.16

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  39 in total

1.  The macrophage response to bacteria. Modulation of macrophage functional activity by peptidoglycan from Moraxella (Branhamella) catarrhalis.

Authors:  R Keller; J E Gustafson; R Keist
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

2.  Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against Moraxella catarrhalis.

Authors:  E Bingen; F Bourgeois; H Chardon; C Doit; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

3.  Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens.

Authors:  M Vaneechoutte; G Verschraegen; G Claeys; A M Van Den Abeele
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

Review 4.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

5.  Efficacy and tolerability of cefixime in otitis media. A multicentre study in over 25,000 children.

Authors:  D H Wu
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated from the nasopharynx of healthy children attending day-care centres in the Czech Republic.

Authors:  H Zemlicková; P Urbásková; V Adámková; J Motlová; V Lebedová; B Procházka
Journal:  Epidemiol Infect       Date:  2006-05-10       Impact factor: 2.451

7.  Esterase electrophoresis: a molecular tool for studying the epidemiology of Branhamella catarrhalis nosocomial infection.

Authors:  B Picard; P Goullet; E Denamur; G Suermondt
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

8.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

9.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 10.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.